Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

NCT03696212 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
18
Enrollment
INDUSTRY
Sponsor class

Stopped Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.

Conditions

Interventions

Sponsor

Arrys Therapeutics

Collaborators